Citadel Advisors
LPCN icon

Citadel Advisors’s Lipocine LPCN Stock Holding History

Citadel Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+29,088
New +$253K ﹤0.01% 11090
2025
Q4 		– Sell
-14,247
Closed -$40.7K – 13486
2025
Q3 		$40.7K Buy
+14,247
New +$43.3K ﹤0.01% 12289
2023
Q2 		– Sell
-5,494
Closed -$29.7K – 14858
2023
Q1 		$29.7K Sell
5,494
-776
-12% -$5.99K ﹤0.01% 12746
2022
Q4 		$40.9K Sell
6,270
-11,107
-64% -$80.9K ﹤0.01% 12381
2022
Q3 		$133K Buy
+17,377
New +$194K ﹤0.01% 10838
2022
Q2 		– Sell
-3,714
Closed -$57.9K – 13589
2022
Q1 		$86K Buy
3,714
+1,620
+77% +$33.9K ﹤0.01% 12419
2021
Q4 		$36K Sell
2,094
-1,178
-36% -$21.9K ﹤0.01% 13409
2021
Q3 		$61K Buy
+3,272
New +$72.2K ﹤0.01% 13255
2021
Q2 		– Sell
-2,457
Closed -$57.8K – 14081
2021
Q1 		$63K Sell
2,457
-1,948
-44% -$56.2K ﹤0.01% 12785
2020
Q4 		$102K Buy
4,405
+3,692
+518% +$88.9K ﹤0.01% 10209
2020
Q3 		$17K Buy
+713
New +$18.9K ﹤0.01% 9886
2020
Q2 		– Sell
-721
Closed -$9.34K – 10208
2020
Q1 		$6K Buy
+721
New +$5.71K ﹤0.01% 9473
2019
Q2 		– Sell
-609
Closed -$24K – 9558
2019
Q1 		$24K Sell
609
-157
-20% -$4.82K ﹤0.01% 9032
2018
Q4 		$17K Buy
+766
New +$17.8K ﹤0.01% 8803
2018
Q3 		– Sell
-964
Closed -$23.7K – 9502
2018
Q2 		$21K Buy
+964
New +$23K ﹤0.01% 8643
2015
Q4 		– Sell
-4,076
Closed -$820K – 8978
2015
Q3 		$820K Buy
+4,076
New +$943K ﹤0.01% 4085

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Citadel Advisors's LPCN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Lipocine (LPCN) in Q1 2026: 29,088 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #11090 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LPCN as recently as Q3 2025.

Citadel Advisors first reported a position in LPCN in Q3 2015 and has held it in 16 quarters since. The position peaked at $820K in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Citadel Advisors held 29,088 shares of Lipocine worth $232K as of Q1 2026.
  • Lipocine was a new Citadel Advisors position in Q1 2026.
  • Lipocine made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11090 holding.
  • Citadel Advisors first reported a position in Lipocine in Q3 2015 and has held it in 16 quarters since.
  • Citadel Advisors's Lipocine position peaked at $820K in Q3 2015.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.